L
LungLife AI
Blood-based tool that has been developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer
About LungLife AI
LungLife AI, Inc. operates as a clinical-stage diagnostic company, focusing on improving the early detection of lung cancer. Previously known as Cynvenio Biosystems, Inc., the company was incorporated in 2009 and is headquartered in Thousand Oaks, California. LungLife AI is led by Chief Executive Officer Paul Pagano, who has over 16 years of experience in chemistry, engineering, and cancer biology, with specialized training in translational lung cancer research from UCLA. His background includes developing a patented microfluidic platform for circulating tumor cell analysis and working in quality analytical laboratories at Amgen Inc.
The company's core business revolves around its flagship product, the LungLB® test. This diagnostic tool is designed to assist clinicians in evaluating indeterminate lung nodules discovered through CT scans, which could be benign tissue or malignant cancer. The market for this service is substantial, with over 1.5 million individuals diagnosed with indeterminate lung nodules annually in the United States alone. LungLife AI's business model is centered on commercializing the LungLB® test, which is performed in its CLIA-certified and CAP-accredited laboratory. Revenue generation is anticipated through reimbursement from medical insurance providers, including a price of $2,030 per test set by the Centers for Medicare & Medicaid Services (CMS), and potential contract fees from pharmaceutical companies for clinical trial support. The company is currently seeking strategic partners to aid in the commercial launch and market penetration of the LungLB® test.
The LungLB® test is a blood-based liquid biopsy that utilizes a minimally invasive blood draw. Its technology combines rare-cell enrichment with a proprietary 4-color fluorescence in situ hybridization (FISH) assay to identify Circulating Genetically Abnormal Cells (CGACs) that exhibit chromosomal abnormalities often found in lung cancer. A key differentiator is the integration of artificial intelligence and machine learning algorithms, developed in partnership with Persistent Systems, to analyze high-resolution 3D images of cells. This AI-driven image analysis automates the classification of abnormal cells, which has been shown to reduce analysis time by nearly 70% and misclassified cells by up to 90%. The test provides clinicians with a binary result—positive or negative for high risk—helping to reduce unnecessary invasive procedures and avoid delays in treatment associated with the 'wait-and-see' approach.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Headquarters
- Thousand Oaks, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
News
Open roles
LungLife AI in the Thousand Oaks ecosystem
The LungLife AI office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Livzon Pharmaceutical Group
Greenwoods Asset Management
Syno Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LungLife AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LungLife AI on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

